Transplantation Characteristics and Recovery Data of the Studied Patients
| . | UPN 345 . | UPN 347 . | UPN 357 . | UPN 363 . |
|---|---|---|---|---|
| Diagnosis | MDS (RA) 5q−, +21 | AML (MDS-RAEB) | ALL | MDS (RAEB) |
| Conditioning regimen | Bu/Cy | Bu/Cy | TBI/Cy | Bu/Cy |
| Transplanted immunoselected CD34+ blood cells × 106/kg on d 0* | 10.3 | 6.0 | 7.2 | 1.5 |
| Transplanted expanded cells† × 106/kg | ||||
| On d | 1.5; 1.0; 1.1; 1.5; 2.0 | 2.0; 3.6 | 1.6; 2.4 | 89.5‡ |
| 0; 2; 4; 6; 8 | 0; 2 | 0; 6 | 0 | |
| % CD34+ cells | 22; 17; 13; 7; 3 | 14; 13 | 17; 36 | 1.2 |
| Expanded from CD34+ cells (×106/kg) | 1.0 | 0.5 | 0.5; 0.7 | ND |
| Expanded for (d in culture) | 7; 9; 11; 13; 15 | 7; 9 | 7; 7 | ND |
| Days to leukocyte recovery (>1 × 109/L) | 13 | 19 | 18 | 15 |
| Days to platelets recovery (>50 × 109/L) | 16 | 38 | Not reached | 26 |
| Days to last platelet/RBC transfusion | 13/13 | 28/24 | Died on day 30 | 20/0 |
| No. transfused platelet/RBC units | 60/6 | 146/8 | 200/18 | 44/0 |
| First day with >90% donor cells | 11 | 14 | ND | 12 |
| . | UPN 345 . | UPN 347 . | UPN 357 . | UPN 363 . |
|---|---|---|---|---|
| Diagnosis | MDS (RA) 5q−, +21 | AML (MDS-RAEB) | ALL | MDS (RAEB) |
| Conditioning regimen | Bu/Cy | Bu/Cy | TBI/Cy | Bu/Cy |
| Transplanted immunoselected CD34+ blood cells × 106/kg on d 0* | 10.3 | 6.0 | 7.2 | 1.5 |
| Transplanted expanded cells† × 106/kg | ||||
| On d | 1.5; 1.0; 1.1; 1.5; 2.0 | 2.0; 3.6 | 1.6; 2.4 | 89.5‡ |
| 0; 2; 4; 6; 8 | 0; 2 | 0; 6 | 0 | |
| % CD34+ cells | 22; 17; 13; 7; 3 | 14; 13 | 17; 36 | 1.2 |
| Expanded from CD34+ cells (×106/kg) | 1.0 | 0.5 | 0.5; 0.7 | ND |
| Expanded for (d in culture) | 7; 9; 11; 13; 15 | 7; 9 | 7; 7 | ND |
| Days to leukocyte recovery (>1 × 109/L) | 13 | 19 | 18 | 15 |
| Days to platelets recovery (>50 × 109/L) | 16 | 38 | Not reached | 26 |
| Days to last platelet/RBC transfusion | 13/13 | 28/24 | Died on day 30 | 20/0 |
| No. transfused platelet/RBC units | 60/6 | 146/8 | 200/18 | 44/0 |
| First day with >90% donor cells | 11 | 14 | ND | 12 |
Abbreviations: RBC, red blood cell; MDS, myelodysplastic syndrome; RA, refractory anemia; AML, acute myeloid leukemia; RAEB, refractory anemia with excess of blasts; ALL, acute lymphoblastic leukemia; Bu/Cy, busulfan (4 × 1 mg/kg/d on days −7 to −4) and cyclophosphamide (60 mg/kg/d for days −3 and −2); TBI/Cy, fractionated total body irradiation (12 Gy, on days −7 to −4) and cyclophosphamide (as above); ND, not done.
The infusion of the nonexpanded graft was standardized on day 0.
Expansion was performed with interleukin-1β (IL-1β), ILl-3, IIL-6, and G-CSF, as published elsewhere.5
Unmanipulated BM.